A recent study suggests that individuals who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end traditional lifestyle programs.
Findings released in a leading health publication demonstrates that while obese people can lose a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month once they quit.
"People purchasing such treatments should be cognizant of the danger of fast rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment mass in about one and a half years.
Analyzing Therapies
The analysis, which examined dozens of studies involving thousands of patients, contrasted the results of the injectable medications with other pills.
The team note that individuals who lose weight through lifestyle changes alone generally see a less rapid creep back—approximately 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Experts believe the way of the injections accounts for the heightened rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which controls hunger.
"Sustained high doses of the hormone concentrations far above than the body's typical production might result in the system to produce less of its endogenous hormone, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating far more likely."
A Chronic Condition?
Health authorities advise the jabs for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, considering the significant potential of relapse, the therapy is often long-term.
This view is supported by drug manufacturers, who state that the findings "emphasize the long-term character of excess weight," comparing it to managing conditions like diabetes.
Patient Testimonies
Users who have stopped the medication report a intense resurgence of hunger.
"I experienced a trigger that goes on and I was suddenly extremely hungry," described a patient.
This difficulty is exacerbated if patients have not adopted lasting dietary or behavioural changes during therapy.
Widespread Adoption
Recent estimates show that a significant number of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is greater among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while these medications are powerful agents for shedding pounds, they are not a permanent solution and lasting health benefits relies on integrated behavioural support.
